Drug Name: 

DUPILUMAB*

Drug Description: 
IL-4R Antibody
Target Condition: 
Atopic dermatitis in pediatrics and adolescents, asthma in adults and adolescents, pediatric asthma, nasal polyps
Rank: 
25
Phase: 
Phase 3